Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Sells 7,080 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jazz Pharmaceuticals Trading Up 1.7 %

Shares of Jazz Pharmaceuticals stock traded up $2.36 during trading on Friday, hitting $138.81. 1,226,548 shares of the company were exchanged, compared to its average volume of 763,953. The firm has a market capitalization of $8.43 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The firm’s fifty day moving average price is $128.14 and its 200 day moving average price is $120.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday. Barclays restated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Morgan Stanley reissued an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $189.40.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC raised its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares during the period. Elequin Capital LP lifted its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.